Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine
| Autor: | Jose R. Almeida, Joffre Rezende-Filho, Naylé V. Leite, Enio Chaves de Oliveira, Mauro Bafutto, Salustiano Gabriel-Neto |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Adult
Diarrhea Male medicine.medical_specialty Abdominal pain Adolescent Síndrome do intestino irritável Anti-Inflammatory Agents Colonoscopy Inflammatory bowel diseases Gastroenterology Irritable Bowel Syndrome chemistry.chemical_compound Bristol stool scale Mesalazine Gastrointestinal Agents Internal medicine Medicine Humans Mesalamina lcsh:RC799-869 Mesalamine Irritable bowel syndrome Gastrointestinal agent medicine.diagnostic_test business.industry Enteropatias inflamatórias digestive oral and skin physiology Anti-Inflammatory Agents Non-Steroidal Abdominal distension Middle Aged medicine.disease Treatment Outcome chemistry lcsh:Diseases of the digestive system. Gastroenterology Female medicine.symptom business |
| Zdroj: | Arquivos de Gastroenterologia, Volume: 48, Issue: 1, Pages: 36-40, Published: MAR 2011 Arquivos de Gastroenterologia v.48 n.1 2011 Arquivos de gastroenterologia Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia instacron:IBEPEGE Arquivos de Gastroenterologia, Vol 48, Iss 1, Pp 36-40 (2011) |
| Popis: | CONTEXT: Recent studies support the hypothesis that postinfectious irritable bowel syndrome and some irritable bowel syndrome patients display persistent signs of minor mucosal inflammation. Mesalazine has intestinal anti-inflammatory properties including cyclooxygenase and prostaglandin inhibition. The effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome patients are still unknown. OBJECTIVE: To observe the effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with diarrhea patients. METHODS: Based on Rome III criteria, 61 irritable bowel syndrome with diarrhea patients (18 years old or more) were included in the evaluation. Patients were divided into two groups: postinfectious irritable bowel syndrome group, with 18 patients medicated with mesalazine 800 mg 3 times a day for 30 days; noninfective irritable bowel syndrome group, with 43 patients medicated with mesalazine 800 mg 3 times a day for 30 days. Symptom evaluations at baseline and after treatment were performed by means of a four-point Likert scale including stool frequency, stool form and consistency (Bristol Stool Scale), abdominal pain and distension (maximum score: 16; minimum score: 4). RESULTS: Postinfectious irritable bowel syndrome group presented a statistically significant reduction of the total symptom score (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|